Blueprint Medicines Corp (BPMC) — Cash Flow-to-Debt Ratio
Blueprint Medicines Corp (BPMC) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2025, meaning its operating cash flow of $-54.48 Million could theoretically repay 0% of its total liabilities ($853.47 Million) in one year. See Blueprint Medicines Corp free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Blueprint Medicines Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Blueprint Medicines Corp across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Blueprint Medicines Corp generate cash.
Annual Cash Flow-to-Debt Ratio for Blueprint Medicines Corp (2013–2024)
Year-by-year debt coverage analysis for Blueprint Medicines Corp. Check Blueprint Medicines Corp (BPMC) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.22x | $-192.59 Million | $881.15 Million | ▲ +54.0% |
| 2023 | -0.48x | $-436.85 Million | $918.64 Million | ▲ +20.9% |
| 2022 | -0.60x | $-502.28 Million | $835.23 Million | ▲ +43.3% |
| 2021 | -1.06x | $-298.65 Million | $281.49 Million | ▼ -168.1% |
| 2020 | 1.56x | $387.04 Million | $248.31 Million | ▲ +236.4% |
| 2019 | -1.14x | $-278.01 Million | $243.34 Million | ▲ +20.9% |
| 2018 | -1.44x | $-175.01 Million | $121.11 Million | ▼ -10.6% |
| 2017 | -1.31x | $-119.86 Million | $91.77 Million | ▼ -271.5% |
| 2016 | -0.35x | $-24.51 Million | $69.72 Million | ▲ +61.2% |
| 2015 | -0.91x | $-31.68 Million | $34.92 Million | ▲ +62.9% |
| 2014 | -2.44x | $-35.40 Million | $14.50 Million | ▲ +27.7% |
| 2013 | -3.38x | $-19.02 Million | $5.63 Million | — |